论文部分内容阅读
目的:观察氨曲南治疗下呼吸道感染的临床疗效和安全性。方法:将90例下呼吸道感染患者随机分为氨曲南组和头孢他啶组各45例。分别给予氨曲南2.0g、头孢他啶2.0g静脉滴注,每隔12h1次,疗程均为7～14d。比较两组临床疗效、细菌清除率及不良反应情况。结果:氨曲南组和头孢他啶组的临床有效率分别为91.11%和86.67%,细菌清除率分别为93.33%、89.13%,两者比较差异均无统计学意义(P>0.05);两组均未发生严重不良反应。结论:氨曲南临床治疗下呼吸道感染安全、有效。
Objective: To observe the clinical efficacy and safety of aztreonam in the treatment of lower respiratory tract infection. Methods: 90 patients with lower respiratory tract infection were randomly divided into aztreonam and ceftazidime group of 45 cases. Respectively given aztreonam 2.0g, ceftazidime 2.0g intravenous infusion, every 12h1 times, treatment were 7 ~ 14d. The clinical efficacy, bacterial clearance and adverse reactions of the two groups were compared. Results: The clinical efficacies of aztreonam and ceftazidime were 91.11% and 86.67%, respectively, and the bacterial clearance rate was 93.33% and 89.13% respectively. There was no significant difference between the two groups (P> 0.05) No serious adverse reactions occurred. Conclusion: Aztreonam is safe and effective in treating lower respiratory tract infection.